Evidence map›Paper›PMID 31282051›Full record

Trial reportThe Journal of dermatology2019

Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa.

Akimichi Morita, Hidetoshi Takahashi, Kentaro Ozawa, Shinichi Imafuku, Takekuni Nakama, Kenzo Takahashi, Takashi Matsuyama, Yukari Okubo, Susumu Kitamura, Naoto Matsuda and 4 more

Open access · hybridAbstract readClinical Trial, Phase IIIMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Trial report in The Journal of dermatology, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.9field-weighted citation impact, top 10% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 17 citations in OpenAlex.

  1. Trial
  2. Observational
  3. Review
  4. Review
  5. Observational
  6. Observational
  7. Review
  8. Quality of Life in Hidradenitis Suppurativa: An Update.International journal of environmental research and public health · 2021
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 11 institutions in 1 country.

Akimichi MoritaNagoya City University Graduate School of Medical Sciences, Nagoya, Japan.ORCID https://orcid.org/0000-0001-8372-3754
Hidetoshi TakahashiTakagi Dermatological Clinic, Hokkaido, Japan.
Kentaro OzawaNational Hospital Organization Osaka National Hospital, Osaka, Japan.
Shinichi ImafukuFukuoka University, Fukuoka, Japan.ORCID https://orcid.org/0000-0001-8568-4349
Takekuni NakamaKurume University School of Medicine, Fukuoka, Japan.
Kenzo TakahashiUniversity of Ryukyus, Okinawa, Japan.
Takashi MatsuyamaTokai University, Tokyo, Japan.
Yukari OkuboTokyo Medical University, Tokyo, Japan.ORCID https://orcid.org/0000-0002-9526-1259
Susumu KitamuraAbbVie GK, Tokyo, Japan.ORCID https://orcid.org/0000-0002-6823-532X
Naoto MatsudaAbbVie GK, Tokyo, Japan.
Yiwei ZhaoAbbVie GK, Tokyo, Japan.
Masayuki YokoyamaAbbVie GK, Tokyo, Japan.
Nobukazu HayashiToranomon Hospital, Tokyo, Japan.ORCID https://orcid.org/0000-0003-1971-230X
Tadashi TeruiNihon University School of Medicine, Tokyo, Japan.
ABB (Japan) · JPFukuoka University · JPKurume University · JPNagoya City University · JPNihon University · JPOsaka National Hospital · JPTakayanagi Dental Clinic · JPTokai University · JPTokyo Medical University · JPToranomon Hospital · JPUniversity of the Ryukyus · JP

Funding

AbbVie
6 · The paper itself

Abstract

Hidradenitis suppurativa (HS) is a chronic skin disease characterized by recurrent painful inflamed nodules/abscesses and draining fistulas that negatively impact quality of life. Adalimumab, a monoclonal antibody against tumor necrosis factor-α, has been approved in the EU, USA and Japan for the treatment of moderate to severe HS. This is an interim analysis of an ongoing phase 3, multicenter, open-label, single-arm study of the safety and efficacy of adalimumab weekly dosing in Japanese patients with moderate to severe HS. Fifteen patients received adalimumab 160 mg at week 0, 80 mg at week 2 and 40 mg every week thereafter starting at week 4. The fulfillment of Hidradenitis Suppurativa Clinical Response was assessed under adalimumab treatment; clinical response was assessed by skin pain, total abscess and inflammatory nodule count and modified Sartorius score; and quality of life and safety were assessed. At week 12, 86.7% of patients achieved clinical response, with improvements at week 12 across the primary and secondary end points generally sustained through week 24. Adalimumab weekly dosing was generally safe and well tolerated with no new safety findings through week 24. These results suggest that adalimumab is effective and well tolerated in Japanese patients with moderate to severe HS.

Indexed as

AdalimumabAdultDose-Response Relationship, DrugDrug Administration ScheduleFemaleHidradenitis SuppurativaHumansJapanMaleMiddle AgedPainPain MeasurementPersonal SatisfactionQuality of LifeSeverity of Illness IndexSurveys and QuestionnairesAdalimumabadalimumabhidradenitishidradenitis suppurativaJapanskin diseases

Identifiers

PMID31282051
PMCPMC6771639
OpenAlexW2958195622

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.